Biotech Values

[DewDiligence]

Albuferon clarification: In #msg-34043876, I said the following:

>>
The primary goal of the study was to show that Albuferon
dosed biweekly was non-inferior in SVR to Pegasys dosed
weekly. Albuferon achieved an SVR of 80% vs 85% for
the Pegasys arm; the 5% difference was less than the 12%
non-inferiority margin in the SPA and hence the trial is
considered a success.
<<

I should have made it clear that the 12% non-inferiority margin specified in the SPA was 2-sided—i.e. the 1-sided margin was only 6%.

Thus, the observed outcome in which Albuferon was 5% worse than Pegasys was a squeaker, not an easy success.